INNPF - Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales | Benzinga
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, reported its financial results for Q2 2023.
The company's CEO, Iris Bincovich, expressed excitement about the positive trajectory and strategic focus on integrating cannabinoids with established drugs.
"We are thrilled with the significant growth we achieved in the second quarter," Bincovich stated. "Our strategic focus is on integrating cannabinoids with existing proven drugs alongside the robust sales from our subsidiary, ...